Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol

Lab Invest. 2023 Aug;103(8):100189. doi: 10.1016/j.labinv.2023.100189. Epub 2023 May 26.

Abstract

In multiple sclerosis (MS), demyelination occurs in the cerebral cortex, and cerebral cortex atrophy correlates with clinical disabilities. Treatments are needed in MS to induce remyelination. Pregnancy is protective in MS. Estriol is made by the fetoplacental unit, and maternal serum estriol levels temporally align with fetal myelination. Here, we determined the effect of estriol treatment on the cerebral cortex in the preclinical model of MS, experimental autoimmune encephalomyelitis (EAE). Estriol treatment initiated after disease onset decreased cerebral cortex atrophy. Neuropathology of the cerebral cortex showed increased cholesterol synthesis proteins in oligodendrocytes, more newly formed remyelinating oligodendrocytes, and increased myelin in estriol-treated EAE mice. Estriol treatment also decreased the loss of cortical layer V pyramidal neurons and their apical dendrites and preserved synapses. Together, estriol treatment after EAE onset reduced atrophy and was neuroprotective in the cerebral cortex.

Keywords: estrogen; experimental autoimmune encephalomyelitis; multiple sclerosis; neurodegeneration; neuroprotection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Atrophy / drug therapy
  • Atrophy / pathology
  • Cerebral Cortex / metabolism
  • Encephalomyelitis, Autoimmune, Experimental* / drug therapy
  • Estriol / pharmacology
  • Estriol / therapeutic use
  • Female
  • Mice
  • Mice, Inbred C57BL
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis* / metabolism
  • Multiple Sclerosis* / pathology
  • Neurodegenerative Diseases*
  • Neuroprotection
  • Pregnancy

Substances

  • Estriol